참고문헌 (35)

1. Next-generation antibody therapies market forecast pp. Visiongain. (2016). 

2. Hoffmann, R. M., Coumbe, B. G. T., Josephs, D. H., Mele, S., Ilieva, K. M., Cheung, A., Tutt, A. N., Spicer, J. F., Thurston, D. E., Crescioli, S. and Karagiannis, S. N. : Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). Oncoimmunology 7, e1395127 (2018). 

   상세보기

3. Jain, N., Smith, S. W., Ghone, S., Tomczuk, B. : Current ADC Linker Chemistry. Pharm Res 32, 3526 (2015). 

   상세보기

4. Gromek, S. M. and Balunas, M. J. : Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates. Curr Top Med Chem 14, 2822 (2015). 

   

5. Masters, J. C., Nickens, D. J., Xuan, D., Shazer, R. L., Amantea, M. : Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs 36, 121 (2018). 

   상세보기

6. Lo-Coco, F., Cimino, G., Breccia, M., Noguera, N. I., Diverio, D., Finolezzi, E., Pogliani, E. M., Di Bona, E., Micalizzi, C., Kropp, M., Venditti, A., Tafuri, A., Mandelli, F. : Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104, 1995 (2004). 

   상세보기

7. Parigger, J., Zwaan, C. M., Reinhardt, D., Kaspers, G. J. : Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia. Expert Rev Anticancer Ther 16, 137 (2016). 

   상세보기

8. Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., Advani, R., Matous, J. V., Ramchandren, R., Rosenblatt, J. D., Huebner, D., Levine, P., Grove, L., Forero-Torres, A. : Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 7, 24 (2014). 

   상세보기

9. Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., Akilov, O. E., Geskin, L., Trotman, J., Taylor, K., Dalle, S., Weichenthal, M., Walewski, J., Fisher, D., Dreno, B., Stadler, R., Feldman, T., Kuzel, T. M., Wang, Y., Palanca-Wessels, M. C., Zagadailov, E., Trepicchio, W. L., Zhang, W., Lin, H. M., Liu, Y., Huebner, D., Little, M., Whittaker, S., Duvic, M. : Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390, 555 (2017). 

   상세보기

10. Suri, A., Mould, D. R., Liu, Y., Jang, G., Venkatakrishnan, K. : Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study. Clin Pharmacol Ther (2018). 

11. Jhaveri, K. : MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Implications for the Future. J Clin Oncol 35, 127 (2017). 

    상세보기

12. Baselga, J., Lewis Phillips, G. D., Verma, S., Ro, J., Huober, J., Guardino, A. E., Samant, M. K., Olsen, S., de Haas, S. L., Pegram, M. D. : Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clin Cancer Res 22, 3755 (2016). 

    상세보기

13. Martinez, M. T., Perez-Fidalgo, J. A., Martin-Martorell, P., Cejalvo, J. M., Pons, V., Bermejo, B., Martin, M., Albanell, J., Lluch, A. : Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. Crit Rev Oncol Hematol 97, 96 (2016). 

    상세보기

14. Kim, S. B., Wildiers, H., Krop, I. E., Smitt, M., Yu, R., Lysbet de Haas, S., Gonzalez-Martin, A. : Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Int J Cancer 139, 2336 (2016). 

    상세보기

15. Castaigne, S., Pautas, C., Terre, C., Raffoux, E., Bordessoule, D., Bastie, J. N., Legrand, O., Thomas, X., Turlure, P., Reman, O., de Revel, T., Gastaud, L., de Gunzburg, N., Contentin, N., Henry, E., Marolleau, J. P., Aljijakli, A., Rousselot, P., Fenaux, P., Preudhomme, C., Chevret, S., Dombret, H. : Acute Leukemia French, A., Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379, 1508 (2012). 

    상세보기

16. Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., Magro, D., De Fabritiis, P., Muus, P., Alimena, G., Mancini, M., Hagemeijer, A., Paoloni, F., Vignetti, M., Fazi, P., Meert, L., Ramadan, S. M., Willemze, R., de Witte, T., Baron, F. : Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol 34, 972 (2016). 

    상세보기

17. Pilorge, S., Rigaudeau, S., Rabian, F., Sarkozy, C., Taksin, A. L., Farhat, H., Merabet, F., Ghez, S., Raggueneau, V., Terre, C., Garcia, I., Renneville, A., Preudhomme, C., Castaigne, S., Rousselot, P. : Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. Am J Hematol 89, 399 (2014). 

    상세보기

18. Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gokbuget, N., O'Brien, S., Wang, K., Wang, T., Paccagnella, M. L., Sleight, B., Vandendries, E., Advani, A. S. : Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med 375, 740 (2016). 

    상세보기

19. https://pharmaphorum.com/news/nice-reassess-pfizer-blood-cancer-drug/ 

20. Anderl, J., Faulstich, H., Hechler, T., Kulke, M. : Antibody-drug conjugate payloads. Methods Mol Biol 1045, 51 (2013). 

    상세보기

21. Lu, J., Jiang, F., Lu, A., Zhang, G. : Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int J Mol Sci 17, 561 (2016). 

    상세보기

22. Junutula, J. R. and Gerber, H. P. : Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy. ACS Med Chem Lett 7, 972 (2016). 

    상세보기

23. Carter, P. J. and Senter, P. D. : Antibody-drug conjugates for cancer therapy. Cancer J 14, 154 (2008). 

    상세보기

24. Ross, P. L. and Wolfe, J. L. : Physical and Chemical Stability of Antibody Drug Conjugates: Current Status. J Pharm Sci 105, 391 (2016). 

    상세보기

25. Hinrichs, M. J., Dixit, R. : Antibody Drug Conjugates: Nonclinical Safety Considerations. AAPS J 17, 1055 (2015). 

    상세보기

26. Strop, P., Delaria, K., Foletti, D., Witt, J. M., Hasa-Moreno, A., Poulsen, K., Casas, M. G., Dorywalska, M., Farias, S., Pios, A., Lui, V., Dushin, R., Zhou, D., Navaratnam, T., Tran, T. T., Sutton, J., Lindquist, K. C., Han, B., Liu, S. H., Shelton, D. L., Pons, J., Rajpal, A. : Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol 33, 694 (2015). 

    상세보기

27. Zhao, H., Peng, P., Longley, C., Zhang, Y., Borowski, V., Mehlig, M., Reddy, P., Xia, J., Borchard, G., Lipman, J., Benimetskaya, L., Stein, C. A. : Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy. J Control Release 119, 143 (2007). 

    상세보기

28. Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illes, A., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P. L., Cunningham, D., Rosta, A., Josephson, N. C., Song, E., Sachs, J., Liu, R., Jolin, H. A., Huebner, D., Radford, J., Group, E.-S. : Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med 378, 331 (2018). 

    상세보기

29. Wang, E. S., Ades, L., Fathi, A. T., Kreuzer, K. A., O'Meara, M. M., Liang, S.-Y., Ravandi, F. : CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML). Journal of Clinical Oncology 35, TPS7066 (2017). 

30. Moore, K. N., Vergote, I., Oaknin, A., Colombo, N., Banerjee, S., Oza, A., Pautier, P., Malek, K., Birrer, M. J. : FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol (2018). 

31. Moore, K. N., Martin, L. P., O'Malley, D. M., Matulonis, U. A., Konner, J. A., Perez, R. P., Bauer, T. M., Ruiz-Soto, R., Birrer, M. J., Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 35, 1112 (2017). 

    상세보기

32. Coiffier, B., Thieblemont, C., de Guibert, S., Dupuis, J., Ribrag, V., Bouabdallah, R., Morschhauser, F., Navarro, R., Le Gouill, S., Haioun, C., Houot, R., Casasnovas, O., Holte, H., Lamy, T., Broussais, F., Payrard, S., Hatteville, L., Tilly, H. : A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol 173, 722 (2016). 

    상세보기

33. Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., Maliakal, P., Govindan, S. V., Sharkey, R. M., Goldenberg, D. M. : Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer 123, 3843 (2017). 

    상세보기

34. Dotan, E., Cohen, S. J., Starodub, A. N., Lieu, C. H., Messersmith, W. A., Simpson, P. S., Guarino, M. J., Marshall, J. L., Goldberg, R. M., Hecht, J. R., Wegener, W. A., Sharkey, R. M., Govindan, S. V., Goldenberg, D. M., Berlin, J. D. : Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol 35, 3338 (2017). 

    상세보기

35. Burris, H. A., Barve, M. A., Hamilton, E. P., Bardia, A., Soliman, H. H., Jarlenski, D., Mosher, R, Bergstrom, D. A. : A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2. Journal of Clinical Oncology 35, TPS2606 (2017). 

저자의 다른 논문 :

신석호 (3) 박민호 (5) 변진주 (2)